Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
about
Improving the clinical impact of biomaterials in cancer immunotherapy.Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and ImmunotherapySynthetic Nanoparticles for Vaccines and ImmunotherapyEngineering New Approaches to Cancer VaccinesIn vivo targeting of adoptively transferred T-cells with antibody- and cytokine-conjugated liposomesThe era of bioengineering: how will this affect the next generation of cancer immunotherapy?CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance.In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapyControl of the adaptive immune response by tumor vasculature.Intratumoral immunization: a new paradigm for cancer therapy.Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells.Microenvironment of tumor-draining lymph nodes: opportunities for liposome-based targeted therapy.Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.Intratumoral immunotherapy for melanoma.Regulatory T cells in the immunotherapy of melanoma.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Development and characterization of naive single-type tumor antigen-specific CD8+ T lymphocytes from murine pluripotent stem cells.Biomaterials for enhancing anti-cancer immunity.Emerging nanotechnologies for cancer immunotherapyNanomedicine approaches to improve cancer immunotherapy.Biphasic effects of propranolol on tumour growth in B16F10 melanoma-bearing mice.Delivering safer immunotherapies for cancer.Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.Immunoengineering with biomaterials for enhanced cancer immunotherapy.Synthetic immune niches for cancer immunotherapy.Control of autoimmune inflammation using liposomes to deliver positive allosteric modulators of metabotropic glutamate receptors.Nanomaterials for cancer immunotherapy.Self-Assembled Nano-Immunostimulant for Synergistic Immune Activation.Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.Multistaged Nanovaccines Based on Porous Silicon@Acetalated Dextran@Cancer Cell Membrane for Cancer Immunotherapy.Treg cells as potential cellular targets for functionalized nanoparticles in cancer therapy.Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses.A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.Cancer vaccines: Material breach.NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention.
P2860
Q26766267-651EB9CC-59F9-4DFB-A8F4-063F692DD7BAQ26782566-4C435CEF-E22F-4F48-BDDB-71C8211A5655Q28085375-EDA9633A-3E86-46A0-9BB5-044C8149299FQ28085563-AD2E783C-E82B-4D8C-A548-8F3B95AE3A2DQ33716478-144873FF-D953-4187-9C80-1464CBDC1BB8Q33815087-84A54576-50C7-4F40-9499-59696929569BQ35600651-6BB2A3A2-7103-4B81-9B15-F9AED16E46B4Q37465136-E5C754BC-9DC0-4C2C-8518-F657421F054CQ37683575-329612C1-13F1-46DA-9A54-E7AC4458A2ADQ37691837-0A096B12-E279-4792-8DFD-04A05064F7AAQ37708824-7DAB1015-1AF0-4A7A-A5A3-C0D3C2977DFEQ38266149-845653CA-58E6-43FE-B543-AA0AFD857463Q38418305-4F9B6BF6-CC91-403A-A37D-BE7B80109636Q38518518-9E53D1D7-06CA-4207-91C4-D69286A8D7A6Q38619815-8AF7DE26-0548-43BC-9AEF-34F44EF1447CQ38677432-6A942256-DAAB-454A-A74D-6EFA47076A82Q38694821-10FF031C-228C-4576-91D9-C6927324083AQ38741829-9A98D6B7-5444-4CE8-9FF4-1350E4468829Q38837036-3F171150-627E-41BA-8906-AAA74CAD825DQ39179977-D4C405C9-98DD-47AE-8477-0DE2D4D5C6FBQ39238169-A85C30B4-DE10-4D5C-819A-70EDE8301E69Q39330984-5134F8DA-0EB3-4794-B32B-62ACB2A564FDQ41945124-A713A1E7-6265-487E-AEB2-46FECB216635Q47203993-E3427CBC-12A3-4C7D-9F84-E1815D3A3E9DQ47732542-0A010F87-DFFF-412F-B40B-A238D004B750Q47739711-D622D5C8-802E-499A-B29F-5057CB7DC2F3Q47846395-854CCDDA-11D4-441B-AF53-C93D060552EFQ48646732-3ED32CBB-0853-45BF-AC8A-F100B35D86D8Q48761437-F0714357-F5FC-48C4-98A5-5CA66BA56BB7Q50426810-D3AB8383-DFCA-4B26-A791-BFD150BD8D2EQ51068276-2F2F5694-F946-4B9A-83A6-E9EB1290ADADQ51799863-50EA0297-1E15-4682-87DC-BEA84B2F002DQ52353493-92520A6E-F9E2-4C90-A6FC-F1B4BA39091FQ52565193-0B5EA73B-BD68-459F-9067-75A68199252AQ53653061-F3D6197C-9BB2-44CD-92CB-829C92DE60B0Q54369697-CBDE1597-A8AF-449F-ABB8-FF68545C38FB
P2860
Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Localized immunotherapy via li ...... d systemic antitumor immunity.
@ast
Localized immunotherapy via li ...... d systemic antitumor immunity.
@en
type
label
Localized immunotherapy via li ...... d systemic antitumor immunity.
@ast
Localized immunotherapy via li ...... d systemic antitumor immunity.
@en
prefLabel
Localized immunotherapy via li ...... d systemic antitumor immunity.
@ast
Localized immunotherapy via li ...... d systemic antitumor immunity.
@en
P2093
P2860
P1433
P1476
Localized immunotherapy via li ...... nd systemic antitumor immunity
@en
P2093
Brandon Kwong
Darrell J Irvine
Jamal Elkhader
S Annie Gai
P2860
P304
P356
10.1158/0008-5472.CAN-12-3343
P407
P577
2013-02-22T00:00:00Z